Immunic Inc

NASDAQ:IMUX   3:59:51 PM EDT
3.73
+0.12 (+3.32%)
Products, Regulatory

Immunic Announces Results Of Early-Stage Trial Of Imu-856 In Healthy Human Subjects

Published: 09/20/2022 10:43 GMT
Immunic Inc (IMUX) - Immunic Announces Positive Results From Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of Imu-856 in Healthy Human Subjects.
Immunic Announces Positive Results From Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of Imu-856 in Healthy Human Subjects.
Immunic Inc - No Maximum Tolerated Dose Reached; Investigated Doses Expected to Exceed Required Therapeutic Dosing of Imu-856.
Immunic Inc - Unblinded Data Revealed a Favorable Safety, Tolerability and Pharmacokinetic Profile for Imu‑856 in Single and 14-day Multiple Dosing.
Immunic Inc - Third Portion of Phase 1 Clinical Trial in Patients With Celiac Disease Ongoing.
Immunic Inc - Treatment Emergent Adverse Events (teaes) Were Mostly Mild in Severity.